4.7 Article

Approach to the Patient With Congenital Hypothyroidism

期刊

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 107, 期 12, 页码 3418-3427

出版社

ENDOCRINE SOC
DOI: 10.1210/clinem/dgac534

关键词

congenital hypothyroidism; thyroid dysgenesis; dyshormonogenesis; central hypothyroidism; genetic model; stem cells

资金

  1. French public nonprofit funding agency Programme Hospitalier de Recherche Clinique HYPOTYGEN [P 110120-IDRCB2012-A00797-36]
  2. EDF
  3. Sandoz SAS
  4. Merck Serono France
  5. nonprofit Princess Grace Foundation of Monaco
  6. Agence Nationale de la Recherche [ANR MITHYPLA/ANR-21-CE14-0055-01]

向作者/读者索取更多资源

Congenital hypothyroidism (CH) is the most common endocrine disorder in newborns and can lead to significant developmental and growth issues if not diagnosed and treated early. Detecting CH through newborn screening programs is cost-effective and highly accurate, but many countries have yet to implement these programs.
Congenital hypothyroidism (CH) is the most frequent neonatal endocrine disorder and the most common preventable cause of development delay and growth failure if diagnosed and treated early. The thyroid is the first endocrine gland to develop during embryonic life and to be recognizable in humans. Thyroid development and maturation can be divided into 2 phases: a first phase of embryogenesis and a second phase of folliculogenesis and differentiation with thyroid hormone production at the final steps. Regulation of the thyroid function requires normal development of the hypothalamic-pituitary-thyroid axis, which occurs during the embryonic and neonatal period. Defects in any of steps of thyroid development, differentiation, and regulation lead to permanent CH. Newborn screening programs, established in only one-third of countries worldwide, detect CH and are cost-effective and highly sensitive and specific. During the last decade, epidemiology of CH has changed with increased frequency of thyroid in situ in primary CH. Advances in molecular testing have expanded knowledge and understanding of thyroid development and function. However, a molecular cause is identified in only 5% of CH due to thyroid dysgenesis. The purpose of this article is to describe the clinical approach to the child with CH, focusing on diagnostic work-up and future challenges on optimizing thyroid replacement therapy and regenerative medicine. The review is written from the perspective of the case of 2 girls referred for CH after newborn screening and diagnosed with thyroid ectopy. The genetic work-up revealed novel mutations in TUBB1 gene, associated with large platelets and abnormal platelet physiology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据